SCHEMBL6723565

SCHEMBL6723565

Cc1ccc(C(=O)C=S(=O)=O)cc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
KCNQ3 O43525 2/20 0.41
KCNQ2 O43526 2/20 0.41
KCNE1 P15382 2/20 0.41
KCNQ1 P51787 2/20 0.41
KCNQ5 Q9NR82 1/20 0.41
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 2/20 0.41
KMT2A Q03164 2/20 0.41
MTOR P42345 1/20 0.40
MEN1 O00255 1/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
SNCA P37840 1/20 0.38
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13623615 0.80 HDAC1 (0.58) HDAC1HDAC6KCNQ3KCNQ2KCNE1
SCHEMBL30881474 0.77 HDAC1 (0.63) HDAC1HDAC6KCNQ3KCNQ2KCNE1
SCHEMBL1926473 0.77 HDAC1 (0.63) HDAC1HDAC6KCNQ3KCNQ2KCNE1
SCHEMBL10703579 0.74 HDAC1 (0.63) HDAC1HDAC6KCNQ3KCNQ2KCNE1
SCHEMBL503345 0.74 HDAC1 (0.63) HDAC1HDAC6KCNQ3KCNQ2KCNE1
SCHEMBL6024134 0.72 HDAC1 (0.61) HDAC1HDAC6KCNQ3KCNQ2KCNE1
SCHEMBL925050 0.72 HDAC1 (0.61) HDAC1HDAC6KCNQ3KCNQ2KCNE1
SCHEMBL12302152 0.72 HDAC1 (0.61) HDAC1HDAC6KCNQ3KCNQ2KCNE1
Hydrochloric Acid SCHEMBL6563896 0.72 HDAC1 (0.61) HDAC1HDAC6KCNQ3KCNQ2KCNE1
SCHEMBL377212 0.72 HDAC1 (0.61) HDAC1HDAC6KCNQ3KCNQ2KCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 HDAC1 718/4885HDAC6 1279/4885KCNQ3 3404/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 HDAC1 732/4885HDAC6 1198/4885KCNQ3 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.